Wall Street Journal17d
Vaccine Stocks Jump on U.S. Bird-Flu Death
Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...
Is Pfizer Stock a Buy?
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
CNBC on MSN10d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...
Emergent BioSolutions: Stock Is A Likely Winner In 2025
BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...
Moderna’s Financial Outlook Dims Amid Vaccine Challenges and Revised Sales Forecasts, Warrants Sell Rating
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
Top 10 Medical AI Stocks on Wall Street’s Radar
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Trump highlights partnership investing $500 billion in AI
President Donald Trump talked up a joint venture investing up to $500 billion for infrastructure tied to AI by a new ...
Hosted on MSN1d
Valneva reports Phase 2 results in children for its chikungunya vaccine
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...